Marcus Hentrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marcus Hentrich has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Christian Hoffmann
IPM Study Center, Hamburg and University of Schleswig Holstein
3 shared publicationsChristoph Wyen
University of Cologne
3 shared publicationsFranz Mosthaf
Hematology, Oncology and Infectious Diseases Practice
3 shared publicationsJan Siehl
Ärzteforum Seestraße
3 shared publicationsMarkus Müller
Vivantes Auguste-Viktoria-Hospital
3 shared publicationsC. Hoffmann
2 shared publications
Latest Publications
- 23 September 2014
- Published by Wiley in HIV Medicine
- Vol. 16 (4) , 261-264
Hodgkin lymphoma is as common as non‐Hodgkin lymphoma in HIV‐positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study
Objectives: The incidence of HIV‐related non‐Hodgkin lymphoma (NHL) but not that of Hodgkin lymphoma (HL) has been declining. The aim of the study was to compare HIV‐infected patients with NHL and HL with respect to antiretroviral therapy (ART) exposure at the time of lymphoma diagnosis.Methods: HIV‐infected patients with NHL and HL included in a prospective multicentre cohort study since January 2005 were compared with respect to ART exposure and viral load at the time of lymphoma diagnosis.Results: As of 31 December 2012, data for 329 patients with NHL and 86 patients with HL from 31 participating centres were available. Patients with HL were more likely to be on ART (73.5% vs. 39.1%, respectively; P < 0.001) and more frequently had a viral load below the detection limit (57.3% vs. 27.9%, respectively; P < 0.001) than patients with NHL. The proportion of patients with HL was 8.0% in ART‐naïve patients, 34.8% in patients with current HIV RNA < 50 HIV‐1 RNA copies/mL, and 50.0% in patients with both HIV RNA < 50 copies/mL for > 12 months and a CD4 cell count of > 200 cells/μL. Of note, 45.8% of all patients with NHL were not currently on ART and had a CD4 count of < 350 cells/μL.Conclusions: This prospective cohort study shows that HL was as common as NHL in patients with sustained viral suppression and limited immune deficiency. In contrast to NHL, the majority of patients with HL were on effective ART, suggesting that ART provides insufficient protection from developing HL. The high proportion of untreated patients with NHL suggests missed opportunities for earlier initiation of ART.
- 23 September 2014
- Published by Wiley in HIV Medicine
- Vol. 16 (4) , 261-264
Hodgkin lymphoma is as common as non‐Hodgkin lymphoma in HIV‐positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study
Objectives: The incidence of HIV‐related non‐Hodgkin lymphoma (NHL) but not that of Hodgkin lymphoma (HL) has been declining. The aim of the study was to compare HIV‐infected patients with NHL and HL with respect to antiretroviral therapy (ART) exposure at the time of lymphoma diagnosis.Methods: HIV‐infected patients with NHL and HL included in a prospective multicentre cohort study since January 2005 were compared with respect to ART exposure and viral load at the time of lymphoma diagnosis.Results: As of 31 December 2012, data for 329 patients with NHL and 86 patients with HL from 31 participating centres were available. Patients with HL were more likely to be on ART (73.5% vs. 39.1%, respectively; P < 0.001) and more frequently had a viral load below the detection limit (57.3% vs. 27.9%, respectively; P < 0.001) than patients with NHL. The proportion of patients with HL was 8.0% in ART‐naïve patients, 34.8% in patients with current HIV RNA < 50 HIV‐1 RNA copies/mL, and 50.0% in patients with both HIV RNA < 50 copies/mL for > 12 months and a CD4 cell count of > 200 cells/μL. Of note, 45.8% of all patients with NHL were not currently on ART and had a CD4 count of < 350 cells/μL.Conclusions: This prospective cohort study shows that HL was as common as NHL in patients with sustained viral suppression and limited immune deficiency. In contrast to NHL, the majority of patients with HL were on effective ART, suggesting that ART provides insufficient protection from developing HL. The high proportion of untreated patients with NHL suggests missed opportunities for earlier initiation of ART.
- 1 May 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (8) , 1445
Erratum to: Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)
- 1 May 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (8) , 1445
Erratum to: Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)
- 29 March 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (6) , 913-921
Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)
AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most common non-AIDS-defining malignancies. Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma) are not available. A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed, Medline, and Cochrane databases. The consensus process was carried out as an e-mail and meeting-based discussion group. Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts) with diffuse large B cell lymphoma (DLBCL). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL/NHL protocol. Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma. Pts with lymphoma in sensitive relapse should receive high-dose chemotherapy followed by autologous stem cell transplantation. Stage- and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts. Combination antiretroviral therapy (cART) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered. Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients.
- 29 March 2014
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (6) , 913-921
Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)
AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most common non-AIDS-defining malignancies. Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma) are not available. A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed, Medline, and Cochrane databases. The consensus process was carried out as an e-mail and meeting-based discussion group. Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts) with diffuse large B cell lymphoma (DLBCL). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL/NHL protocol. Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma. Pts with lymphoma in sensitive relapse should receive high-dose chemotherapy followed by autologous stem cell transplantation. Stage- and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts. Combination antiretroviral therapy (cART) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered. Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients.
- Open Access
- 7 January 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (5) , 936-947
Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
Cancer patients are at increased risk for central venous catheter-related infections (CRIs). Thus, a comprehensive, practical and evidence-based guideline on CRI in patients with malignancies is warranted. A panel of experts by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) has developed a guideline on CRI in cancer patients. Literature searches of the PubMed, Medline and Cochrane databases were carried out and consensus discussions were held. Recommendations on diagnosis, management and prevention of CRI in cancer patients are made, and the strength of the recommendation and the level of evidence are presented. This guideline is an evidence-based approach to the diagnosis, management and prevention of CRI in cancer patients.
- 7 January 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (5) , 936-947
Open AccessCentral venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
Cancer patients are at increased risk for central venous catheter-related infections (CRIs). Thus, a comprehensive, practical and evidence-based guideline on CRI in patients with malignancies is warranted. A panel of experts by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) has developed a guideline on CRI in cancer patients. Literature searches of the PubMed, Medline and Cochrane databases were carried out and consensus discussions were held. Recommendations on diagnosis, management and prevention of CRI in cancer patients are made, and the strength of the recommendation and the level of evidence are presented. This guideline is an evidence-based approach to the diagnosis, management and prevention of CRI in cancer patients.
- 20 November 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (33) , 4117-4123
Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study
Purpose: Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL. Patients and Methods: Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD. Results: Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/μL. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%). Conclusion: In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL.
- 20 November 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (33) , 4117-4123
Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study
Purpose: Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL. Patients and Methods: Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD. Results: Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/μL. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%). Conclusion: In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 8044
PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a retrospective study.
8044 Background: No data are available on using PET-scans in HIV-HL. The goal of the present study is to analyse consecutive patients (pts) with HIV-HL who had at least one PET scan conducted during their course of primary chemotherapy (CT). Methods: In the German prospective multicenter trial pts. with HIV-HL are planned to receive 2x ABVD + 30 Gy involved field (IF) radiation (RT) for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline or 4x ABVD + 30 Gy IF for ES unfavourable HL, and 6-8 x BEACOPP baseline for advanced stage HL with BEACOPP being replaced by ABVD in pts with far advanced HIV-infection or poor performance status. Since the role of PET-scans is not specifically addressed in this trial FDG-PET is not routinely scheduled. However, as PET-scans are being performed on physician’s choice we retrospectively analyzed results and clinical impact of FDG-PET in this cohort of pts. Results: From 03/04 to 12/10 105 pts (median age 43.9 yrs, 8 females) were included in the trial. 23 pts (22%) had ES favourable HL, 14 (13%) ES unfavourable HL, and 68 (65%) advanced stage HL. 26 of 105 pts had a total of 37 PET/PET-CT scans done at some point during their course of treatment. FDG-PET was conducted as part of the initial staging and for response assessment in 8 and 28 cases, respectively. 1 pt had a PET-scan performed to rule out a late relapse of HL or a second malignancy. A negative FDG-PET had an impact on further management in 15 pts with additional RT being omitted in 9 pts and CT for advanced HL being terminated after 6 or 7 cycles of BEACOPP in 5 pts and 1 pt, respectively. A PET-scan performed after 2 cycles of ABVD (PET2) proved negative (neg) in 3/3 pts with 2 of those not receiving IF-RT. PET4 proved negative in 4 of 5 pts with ES-unfavourable HL with IF-RT not being given in all PET4 neg. pts. All PET2/PET4 neg. pts who did not receive IF-RT (n=6) remain disease-free after a median follow-up of 24 months. RT was also successfully omitted in 3 pts with neg. FDG-PET after 6 or 8 cycles of CT. Conclusions: Given the high negative predictive value of FDG-PET in HIV-negative HL, these preliminary data suggest that in pts with HIV-HL a negative PET-scan conducted after 2, 4 or 6-8 cycles of CT may allow the omission of IF-RT.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 8044
PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a retrospective study.
8044 Background: No data are available on using PET-scans in HIV-HL. The goal of the present study is to analyse consecutive patients (pts) with HIV-HL who had at least one PET scan conducted during their course of primary chemotherapy (CT). Methods: In the German prospective multicenter trial pts. with HIV-HL are planned to receive 2x ABVD + 30 Gy involved field (IF) radiation (RT) for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline or 4x ABVD + 30 Gy IF for ES unfavourable HL, and 6-8 x BEACOPP baseline for advanced stage HL with BEACOPP being replaced by ABVD in pts with far advanced HIV-infection or poor performance status. Since the role of PET-scans is not specifically addressed in this trial FDG-PET is not routinely scheduled. However, as PET-scans are being performed on physician’s choice we retrospectively analyzed results and clinical impact of FDG-PET in this cohort of pts. Results: From 03/04 to 12/10 105 pts (median age 43.9 yrs, 8 females) were included in the trial. 23 pts (22%) had ES favourable HL, 14 (13%) ES unfavourable HL, and 68 (65%) advanced stage HL. 26 of 105 pts had a total of 37 PET/PET-CT scans done at some point during their course of treatment. FDG-PET was conducted as part of the initial staging and for response assessment in 8 and 28 cases, respectively. 1 pt had a PET-scan performed to rule out a late relapse of HL or a second malignancy. A negative FDG-PET had an impact on further management in 15 pts with additional RT being omitted in 9 pts and CT for advanced HL being terminated after 6 or 7 cycles of BEACOPP in 5 pts and 1 pt, respectively. A PET-scan performed after 2 cycles of ABVD (PET2) proved negative (neg) in 3/3 pts with 2 of those not receiving IF-RT. PET4 proved negative in 4 of 5 pts with ES-unfavourable HL with IF-RT not being given in all PET4 neg. pts. All PET2/PET4 neg. pts who did not receive IF-RT (n=6) remain disease-free after a median follow-up of 24 months. RT was also successfully omitted in 3 pts with neg. FDG-PET after 6 or 8 cycles of CT. Conclusions: Given the high negative predictive value of FDG-PET in HIV-negative HL, these preliminary data suggest that in pts with HIV-HL a negative PET-scan conducted after 2, 4 or 6-8 cycles of CT may allow the omission of IF-RT.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8035
HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.
8035 Background: The outcome of patients (pts) with HIV-HL has improved since the introduction of highly active antiretroviral therapy (HAART). The current trial was initiated to investigate a risk adapted treatment strategy in pts with HIV-HL as established in HIV-negative pts with HL. Methods: Pts were planned to receive 2x ABVD + 30 Gy involved field (IF) radiation for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline + 30 Gy IF for ES unfavourable HL (extranodal involvement, large mediastinal mass, ≥ 3 lymph node areas involved), and 6-8 × BEACOPP baseline for advanced stage HL. BEACOPP should be replaced by ABVD in pts with far advanced HIV-infection. HAART was given concomitantly with chemotherapy. The primary endpoint was tolerability and treatment related mortality. Secondary endpoints include event free survival (EFS) and overall survival (OS). Results: 93 pts (7 females) were included in the trial. 18/93 pts (19%) had ES favourable HL, 13 (14%) ES unfavourable HL, and 62 (67%) advanced stage HL. 23/87 pts (26%) had a prior AIDS defining illness. The median CD4 count at HL diagnosis was 212/μ l. Grade 3/4 toxicity occurred in 69% under ABVD and 79% under BEACOPP. 4 pts with advanced stage HL died of neutropenic sepsis after the first, seventh (n=2) and eighth course of BEACOPP, respectively. So far response data are available from 78 pts. After a median follow-up of 13.5 months 19/19 pts (100%) with ES favourable HL and 11/11 pts (100%) with ES unfavourable HL achieved a CR/CRu. In pts with advanced HL the CR/CRu rate was 83% (40/48). Of 5 pts having relapsed 2 received an autologous stem cell transplant resulting in a second remission. 7 of 93 pts (8%) have died. Apart from neutropenic sepsis causes of death were progressive HL (n=2) and progressive HIV-infection (PML, n=1). The 12-months OS of the entire study population is 88.3%. EFS and OS are significantly longer in pts with ES HL than in advanced stage HL (p=0.021 and 0.047, respectively). Conclusions: In pts with HIV-HL risk-adapted CT and concomitant HAART is feasible and effective. However, pts must closely be monitored for neutropenic infections. These data suggest that the prognosis of HIV-HD may approach results achieved in the HIV-negative population with HL.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8035
HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.
8035 Background: The outcome of patients (pts) with HIV-HL has improved since the introduction of highly active antiretroviral therapy (HAART). The current trial was initiated to investigate a risk adapted treatment strategy in pts with HIV-HL as established in HIV-negative pts with HL. Methods: Pts were planned to receive 2x ABVD + 30 Gy involved field (IF) radiation for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline + 30 Gy IF for ES unfavourable HL (extranodal involvement, large mediastinal mass, ≥ 3 lymph node areas involved), and 6-8 × BEACOPP baseline for advanced stage HL. BEACOPP should be replaced by ABVD in pts with far advanced HIV-infection. HAART was given concomitantly with chemotherapy. The primary endpoint was tolerability and treatment related mortality. Secondary endpoints include event free survival (EFS) and overall survival (OS). Results: 93 pts (7 females) were included in the trial. 18/93 pts (19%) had ES favourable HL, 13 (14%) ES unfavourable HL, and 62 (67%) advanced stage HL. 23/87 pts (26%) had a prior AIDS defining illness. The median CD4 count at HL diagnosis was 212/μ l. Grade 3/4 toxicity occurred in 69% under ABVD and 79% under BEACOPP. 4 pts with advanced stage HL died of neutropenic sepsis after the first, seventh (n=2) and eighth course of BEACOPP, respectively. So far response data are available from 78 pts. After a median follow-up of 13.5 months 19/19 pts (100%) with ES favourable HL and 11/11 pts (100%) with ES unfavourable HL achieved a CR/CRu. In pts with advanced HL the CR/CRu rate was 83% (40/48). Of 5 pts having relapsed 2 received an autologous stem cell transplant resulting in a second remission. 7 of 93 pts (8%) have died. Apart from neutropenic sepsis causes of death were progressive HL (n=2) and progressive HIV-infection (PML, n=1). The 12-months OS of the entire study population is 88.3%. EFS and OS are significantly longer in pts with ES HL than in advanced stage HL (p=0.021 and 0.047, respectively). Conclusions: In pts with HIV-HL risk-adapted CT and concomitant HAART is feasible and effective. However, pts must closely be monitored for neutropenic infections. These data suggest that the prognosis of HIV-HD may approach results achieved in the HIV-negative population with HL.
- 1 March 2010
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 14, e117
Recent trends of Candida epidemiology in cancer and non-cancer patients
- 1 March 2010
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 14, e117
Recent trends of Candida epidemiology in cancer and non-cancer patients